Advertisement
UK markets close in 3 hours 52 minutes

  • FTSE 100

    8,086.86
    +42.05 (+0.52%)
     

  • FTSE 250

    19,800.92
    +1.20 (+0.01%)
     

  • AIM

    754.84
    -0.03 (-0.00%)
     

  • GBP/EUR

    1.1638
    +0.0010 (+0.09%)
     

  • GBP/USD

    1.2437
    -0.0016 (-0.13%)
     

  • Bitcoin GBP

    53,528.68
    +456.57 (+0.86%)
     

  • CMC Crypto 200

    1,434.36
    +10.26 (+0.72%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     

  • GOLD FUTURES

    2,329.30
    -12.80 (-0.55%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,187.30
    +49.65 (+0.27%)
     

  • CAC 40

    8,134.68
    +28.90 (+0.36%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca drops early head and neck cancer drug plans

Reuters - UK Focus

LONDON, Nov 10 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Thursday it had given up on the idea of seeking an early approval of its immunotherapy drug durvalumab in head and neck cancer using mid-stage Phase II clinical trials data.

The move follows recent changes in the competitive landscape, which has seen Merck (LSE: 0O14.L - news) 's similar Keytruda approved for the condition, reducing the case for special regulatory treatment of durvalumab.

The decision to drop early filing plans in head and neck cancer follows a similar outcome in lung cancer, where AstraZeneca was also too late because Keytruda and Bristol-Myers Squibb's Opdivo had already won approval.

The drugmaker's main hopes for durvalumab, however, are unaffected, since its big potential lies in helping previously untreated lung cancer patients, where it has shown promise when given as part of a combination therapy. (Reporting by Ben Hirschler; editing by Jason Neely)